What Antabio does

Antabio is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Labège, France (near Toulouse), developing novel antibacterial treatments that target drug-resistant pathogens identified as critical priorities by the WHO and CDC. The company is led by founding CEO Marc Lemonnier and supported by a leadership team drawn predominantly from Novexel, GSK, Pfizer, AstraZeneca, and Boehringer Ingelheim. With approximately 30 employees, Antabio operates a lean R&D model focused on small-molecule therapeutics rather than biologics, and has raised more than €50 million cumulatively across equity rounds and non-dilutive grants.

The company's core asset is MEM-PIL (meropenem-pilabactam, formerly MEM-ANT3310), a next-generation β-lactam/β-lactamase inhibitor combination in which pilabactam — a proprietary diazabicyclooctane (DBO) inhibitor — uniquely blocks Class A, C, and D serine beta-lactamases to restore meropenem efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa. MEM-PIL completed Phase 1 in September 2024 and is in Phase 2 preparation. The pipeline additionally includes ANT2681 (a metallo-beta-lactamase inhibitor for NDM-producing CRE), PEi (an inhaled Pseudomonas elastase inhibitor for chronic respiratory disease), ANT3273 (a Pseudomonas biofilm inhibitor for cystic fibrosis), and two discovery platforms: AGAR-dp, a three-project collaboration with GARDP, and INTABIO-dp, an internal novel-target program.

Antabio has no commercial revenue and no approved products; its business model relies on non-dilutive grant funding (Wellcome Trust, CARB-X, Bpifrance, French ARPEGE program) for current R&D operations, with planned future revenue from out-licensing or co-development partnerships with large pharmaceutical companies holding hospital sales infrastructure, and ultimately from product sales concentrated in hospital ICUs and infectious disease specialty channels. The company holds FDA QIDP designations on both MEM-PIL and ANT2681, providing five-year data exclusivity extensions and priority review eligibility, plus EMA PRIME designation on MEM-PIL. Key institutional and strategic investors include AMR Action Fund (Series B lead), EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment.

Name

Antabio

Legal name

ANTABIO

Website

https://antabio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Antabio is a clinical-stage French biopharmaceutical company developing novel antibacterial resistance-breakers, with lead candidate MEM-PIL (meropenem-pilabactam) targeting severe hospital infections caused by WHO/CDC critical priority pathogens including CRAB, CRE, and Pseudomonas aeruginosa.

Ownership category

akta.pro rank

Product category

Infectious Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antibacterial drug development
• Beta-lactamase inhibitors
• Antimicrobial resistance therapeutics
• Hospital infection treatments
• Carbapenem-resistant infections

Headquarters

HQ city

Labège

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of novel antibacterial drugs, once approved. The company is developing treatments for severe hospital infections targeting WHO and CDC critical priority pathogens. Given the QIDP and Fast Track designations, the company may pursue accelerated approval pathways.
2. Licensing and Partnership Deals: Potential licensing agreements with larger pharmaceutical companies for development and commercialization rights in specific territories or indications.
3. Non-Dilutive Funding: Grants and awards from organizations such as Wellcome Trust, CARB-X, and government programs (French government ARPEGE program) to fund R&D activities.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

Core offering

Antabio is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs, principally a next-generation beta-lactam/beta-lactamase inhibitor combination (meropenem-pilabactam, MEM-PIL) for treating life-threatening multi-drug-resistant infections in hospital wards and ICUs. Its pipeline also includes an inhaled Pseudomonas elastase inhibitor for chronic respiratory diseases and early-stage metallo-beta-lactamase inhibitors targeting WHO and CDC critical priority pathogens.

Product overview

Antabio is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel antibacterial treatments targeting WHO and CDC critical-priority drug-resistant pathogens. The core product is MEM-PIL (meropenem-pilabactam), a next-generation β-lactam/β-lactamase inhibitor combination for severe hospital infections. Supporting programs include PEi (Pseudomonas Elastase Inhibitor) for chronic respiratory diseases, ANT2681 (Metallo Beta-Lactamase Inhibitor) for NDM-producing CRE, and ANT3273 for cystic fibrosis. Discovery platforms AGAR-dp (with GARDP) and INTABIO-dp advance additional novel mechanisms through hit-to-lead development.

Differentiator

Problem solved

Functional benefit

Brands

• MEM-PIL (formerly MEM-ANT3310): Meropenem-Pilabactam, a next-generation beta-lactam/beta-lactamase inhibitor combination for treating multi drug-resistant infections in hospital wards and ICUs
• PEi
• ANT2681
• AGAR-dp
• INTABIO-dp

Products and services

• MEM-PIL (Meropenem-Pilabactam) Next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination combining meropenem with pilabactam (formerly ANT3310), designed to treat life-threatening multi drug-resistant infections in hospital wards and ICUs. Targets carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa, as well as susceptible Gram-positives and anaerobes. Currently in clinical development with FDA QIDP designation for cUTI, cIAI, HABP, VABP and EMA PRIME designation.
• PEi (Pseudomonas Elastase Inhibitors) Inhaled small-molecule drug targeting the LasB elastase virulence factor of Pseudomonas aeruginosa, designed as an adjunct to existing antibiotic therapy for chronic respiratory diseases including bronchiectasis, cystic fibrosis, asthma, and COPD. Administered via nebulizer to reduce tissue damage and enhance pathogen clearance. Funded by CARB-X and Wellcome Trust.
• ANT2681 (Metallo Beta-Lactamase Inhibitor) Novel metallo beta-lactamase inhibitor combined with meropenem for treatment of MBL-producing carbapenem-resistant Enterobacterales, particularly NDM-producing strains. Restores meropenem susceptibility in over 90% of NDM-producing clinical isolates of Enterobacteriaceae. Holds FDA QIDP designation for cUTI.
• ANT3273 (Pseudomonas Biofilm/Lung Infection Inhibitor) Novel class, novel mode of action treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary diseases. Funded by Wellcome Trust and CARB-X for cystic fibrosis applications.

Quantifiable outcome

• ANT3310 restores meropenem susceptibility in 95% of A. baumannii clinical isolates tested
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and major.

• GARDP (Global Antibiotic Research & Development Partnership)coreStrategic or Co-development Partner · 23 March 2026Joint collaboration to accelerate early-stage antibiotic discovery, focusing on hit-to-lead projects targeting carbapenem-resistant Gram-negative bacteria. GARDP brings its discovery programme with 280,000+ compounds screened, while Antabio contributes its expertise in medicinal chemistry, microbiology, and early ADMET profiling. The partnership aims to advance novel treatments for life-threatening infections from WHO priority pathogens.
• bioMérieuxmajorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium focused on improving diagnostics for antibiotic resistance through AI-powered sequencing-based susceptibility testing solutions. bioMérieux contributes its expertise in in vitro diagnostics to optimize patient care and reduce healthcare costs.
• Hospices Civils de Lyon (HCL)majorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium for developing EpiTrack - an automated real-time epidemic surveillance system for early detection of resistant bacteria outbreaks in hospitals.
• Toulouse School of Economics (TSE)majorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium developing new economic models for sustainable enhancement of antibiotic innovation value. Led by Jean Tirole (2014 Nobel Prize in Economics).
• Argenta (Galapagos NV)coreTechnology or Integration · 10 March 2014Drug discovery collaboration funded by Wellcome Trust. Argenta provided medicinal chemistry, computer-aided drug design, and ADME/PK services. Successfully achieved milestone identifying novel lead series of pan-metallo beta-lactamase inhibitors.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Achaogen: Developed plazomicin (Zemdri) for complicated UTIs caused by MDR Enterobacteriaceae; filed for bankruptcy shortly after FDA approval in 2018. Important cautionary comparable demonstrating the antibiotic commercial market risk that Antabio also faces.
• Melinta Therapeutics: Developed delafloxacin (Baxdela) for acute bacterial skin infections and CABP. Filed for bankruptcy in 2019 and was acquired by Cempra. Notable as a cautionary comparable illustrating the commercial challenges of novel antibiotic launches.
• Paratek Pharmaceuticals: Developed and commercialized omadacycline (Nuzyra) for CABP and ABSSSI, a tetracycline-class antibiotic active against MDR pathogens. Acquired by Gurnet Point Capital and Novo Holdings in 2023. Comparable as a developer of novel mechanism antibiotics for serious infections.
• Tetraphase Biosciences: Developed eravacycline (Xerava) for complicated intra-abdominal and urinary tract infections caused by MDR pathogens, including carbapenem-resistant Enterobacteriaceae. Acquired by La Jolla Pharmaceutical Company in 2020. Closely comparable in target indications and mechanism class.
• Spero Therapeutics: Clinical-stage biopharmaceutical company developing novel antibiotics for MDR Gram-negative infections, including tebipenem pivoxil and SPR206 (a polymyxin). Comparable as a similarly-staged developer of novel mechanism antibiotics targeting WHO priority pathogens.
• VenatoRx Pharmaceuticals: Clinical-stage antibacterial developer with leading program cefepime-taniborbactam targeting MDR Gram-negative infections including CRE. Most direct comparable as a similarly-sized, similarly-staged developer of beta-lactam/beta-lactamase inhibitor combinations targeting WHO priority pathogens.
• Entasis Therapeutics: Developed sulbactam-durlobactam (Xacduro) for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, approved by FDA in 2023. Acquired by Innoviva. Directly comparable as developer of beta-lactamase inhibitor combinations targeting the same WHO priority pathogens as Antabio.
• Iterum Therapeutics: Clinical-stage company developing oral and IV antibiotics (sulopenem) for Gram-negative infections including complicated UTIs. Comparable as a similarly-staged developer targeting multi-drug resistant Gram-negative pathogens with hospital-focused positioning.

Emerging players

• Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other serious infections. Adjacent comparable as a developer of novel anti-infective approaches targeting resistant pathogens, though using a fundamentally different biological modality.

Broad incumbents

• Shionogi: Large Japanese pharmaceutical company that developed and commercialized cefiderocol (Fetroja) for MDR Gram-negative infections including CRAB, CRE, and Pseudomonas. Direct competitive incumbent to Antabio's MEM-PIL with established hospital commercialization infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/antabio-sas
• Xx.com/antabio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds17 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antabio